Autolus
autolus.com
Actively hiring
Oncology Therapeutics
Cell & Gene Therapy
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Grants
$567k
1 grant · CORDIS
Backers
1
Nextech Invest
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 1
Won a grant $567k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jul 2026 | $567k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Nextech Invest Similar startupsby what they do, their industry and backers
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
BREYANZI® (lisocabtagene maraleucel) is a CD19-directed, genetically modified, autologous T-cell immunotherapy for adult patients with…
Generate the optimized scFvs to yield CAR-T cells with robust anti-tumor effect.
Umoja Biopharma pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells and generate lasting remission.
News
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical c...
Read more
Report
FDA Grants RMAT Designation To Autolus' Obe-cel For Lupus
Autolus Therapeutics plc (AUTL) today announced that the U.S. FDA has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus and lupus nephritis.
Read more
Report
Autolus Posts $75 Million In First-Year AUCATZYL Sales, Guides Up To $135 Million For 2026
Autolus Therapeutics announced it expects preliminary unaudited net product revenue from AUCATZYL (obecabtagene autoleucel; obe-cel) of about $24 million for the fourth quarter of 2025 and about $75 million for the full year, marking its first year of com
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$567k
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2026 | $567k | Details |